Back | Next |
home / stock / gild / gild message board
Subject | By | Source | When |
---|---|---|---|
Gilead Sciences Inc ($GILD) | mick | investorshub | 03/12/2022 8:03:28 PM |
Gilead Sciences Inc ($GILD) | mick | investorshub | 02/15/2022 9:33:38 PM |
Gilead Sciences Inc ($GILD) | mick | investorshub | 02/06/2022 10:27:48 PM |
$GILD owes ViiV* $1.25B+ 3% royalty on US Biktarvy sales, | DewDiligence | investorshub | 02/02/2022 12:04:10 AM |
$GILD 4Q21 results | DewDiligence | investorshub | 02/01/2022 9:08:45 PM |
https://www.otcmarkets.com/stock/$GILD | mick | investorshub | 01/02/2022 11:12:00 PM |
GILD vs $BMY in LBCL$ CAR-Twho has the edge? | DewDiligence | investorshub | 12/14/2021 12:04:16 AM |
https://www.otcmarkets.com/stock/$GILD | mick | investorshub | 12/12/2021 12:17:35 AM |
$GILD and$ MTNB have been working on ORAL | dhbuzz | investorshub | 12/09/2021 4:13:41 PM |
VIR/$GILD start phase-2 trial testing quadruple regimen of | DewDiligence | investorshub | 12/09/2021 3:06:27 PM |
I Agree: https://www.griproom.com/fun/pfizers-covid-pill-might-not-be-as-great-a | Michel | investorshub | 11/08/2021 12:09:56 PM |
Showtime this week! Brilacidin is a BEAST. Remdesivir | Ultimate01 | investorshub | 11/08/2021 12:05:18 PM |
Gilead Sciences Inc ($GILD) | mick | investorshub | 11/07/2021 5:27:25 PM |
i think so they got ah good pipeline though | mick | investorshub | 11/07/2021 5:27:17 PM |
http://www.ipharminc.com/press-release/2020/9/15/laboratory-testing-of-brilacidi | Michel | investorshub | 11/02/2021 11:33:38 AM |
Mick, I think we are the only ones | slimhere | investorshub | 10/29/2021 2:36:58 PM |
$15 under wow | mick | investorshub | 10/28/2021 9:11:11 PM |
Gilead Sciences Inc ($GILD) | mick | investorshub | 10/28/2021 9:10:40 PM |
5PM, we'll see how close you are, I'm | slimhere | investorshub | 10/28/2021 7:09:44 PM |
$gild should be over $80 to $100 imho | mick | investorshub | 10/10/2021 4:18:04 PM |
News, Short Squeeze, Breakout and More Instantly...
– Analysis Comparing Real-World and Clinical Trial Data Show Yescarta ® Has Higher Manufacturing Success Rates and Improved T-Cell Performance, Respectively, in Second-Line vs. Third-Line+ Treatment of Large B-cell Lymphoma – – Encore Oral Present...
-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody -- -- Anito-cel will be manufactured from Kite’s Frederick, Maryland facility for iMMagine-3 as th...
NORTHAMPTON, MA / ACCESSWIRE / May 9, 2024 / A 22-year-old college student who didn't feel well was treated at an urgent care facility in Baton Rouge, Louisiana and expected to recover soon. But when his symptoms worsened, he returned to the emergency department and was given a more thorough che...